Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
Sunshine Biopharma Inc. (SBFM) reports that Dr. Steve N. Slilaty, its Chief Executive Officer and Chairman and holder of approximately 97% of total voting power, approved by written consent an amendment permitting the board to effect a reverse split at a whole-number ratio of up to 1-for-20. The board may choose whether to proceed or abandon the action.
As of September 15, 2026, 4,310,301 common shares were outstanding; the split would leave 215,515 shares at 1-for-20 to 2,155,150 shares at 1-for-2, subject to fractional-share rounding. The stated purpose is to address Nasdaq’s $1.00 minimum bid-price rule. Sunshine says its shares recently traded below that threshold and that through June 2027 it is subject to an immediate delisting notice if it fails the rule for 30 consecutive business days, with the right to request an appeal. It cautions that the split may not ensure continued listing compliance. A split would take effect upon filing an amendment with Colorado’s Secretary of State.
Sunshine Biopharma Inc. (SBFM) has obtained written consent from its majority voting holder, Chief Executive Officer Dr. Steve N. Slilaty, who controls approximately 97% of the total voting power, to amend its articles of incorporation to authorize a reverse stock split of the common stock at a ratio of up to 1-for-20, with the exact whole-number ratio and timing left to the Board’s discretion and with authority to abandon the action.
The stated primary purpose is to help maintain compliance with Nasdaq’s minimum $1.00 bid price requirement and preserve the listing on the Nasdaq Capital Market, following a prior reverse split completed in June 2026 that keeps the company subject to immediate delisting risk through June 2027 if the bid price test is again breached. As of September 15, 2026, there were 4,310,301 common shares outstanding; depending on the ratio chosen, outstanding common shares would be reduced to between 215,515 (1-for-20) and 2,155,150 (1-for-2), with fractional shares rounded up to the next whole share and no change to authorized share counts.
Sunshine Biopharma Inc. (SBFM) reports that on September 15, 2026, its chief executive officer, Dr. Steve N. Slilaty, acting as holder of a majority of the voting power, approved by written consent an authorization for the board to implement a reverse split of the company’s common stock at a ratio of up to 1-for-20. The board has discretion whether to implement the reverse split and to set the exact whole-number ratio up to 1-for-20. The shareholder consent becomes effective 20 days after a definitive information statement describing the action is mailed to stockholders.
Sunshine Biopharma Inc. (SBFM) reports a change to the terms of its outstanding Series B Warrants. Due to recent sales of its common stock under a previously disclosed at-the-market offering, the exercise price of these Series B Warrants has been reduced to $1.2046 per share, subject to further adjustment as provided in the warrant terms.
The company’s common stock (par value $0.001) trades under the symbol SBFM and its common stock purchase warrants trade under SBFMW on The Nasdaq Stock Market LLC.
Sunshine Biopharma Inc. (SBFM) is registering 25,477,133 shares of common stock issuable upon exercise of its outstanding Series B Warrants at a current exercise price of $1.2202 per share, implying maximum gross proceeds of $31,087,198 if all warrants are exercised for cash. The warrants expire on February 15, 2029 and their exercise price and share count are subject to anti-dilution adjustments. The company estimates net proceeds of about $31 million, to be used for general corporate purposes, including working capital. Sunshine Biopharma operates through subsidiaries Nora Pharma Inc. (60 generic prescription drugs in Canada) and Sunshine Biopharma Canada Inc. (OTC supplements), and is also developing K1.1 mRNA for liver cancer and SBFM-PL4 for SARS coronavirus infections. Risks highlighted include potential Nasdaq delisting if it cannot maintain the minimum bid price and a proposed $5 million Market Value of Listed Securities requirement, as well as significant potential dilution from 29,512,762 outstanding warrants.
Sunshine Biopharma Inc. (SBFM) has filed a Form S-1 to register 25,477,133 shares of common stock issuable upon exercise of its outstanding Series B Warrants. The warrants, issued in a February 15, 2024 public offering, currently have a per share exercise price of $1.2202 and expire on February 15, 2029. The registration is intended to permit the warrants to be exercised for cash rather than on a cashless basis.
If all Series B Warrants are exercised for cash at the current price, Sunshine Biopharma would receive gross proceeds of $31,087,198, or approximately $31 million net, which it plans to use for general corporate purposes, including working capital. The company’s common stock trades on Nasdaq under “SBFM,” with a last reported sale price of $1.27 on August 27, 2026. The prospectus highlights Nasdaq listing risk: the company recently effected multiple reverse stock splits and remains vulnerable to delisting for bid-price noncompliance and to a proposed new $5 million Market Value of Listed Securities requirement that it does not currently meet. Sunshine Biopharma also discloses 29,512,762 outstanding warrants, indicating potential future dilution.
Sunshine Biopharma Inc. (SBFM) reported that on August 25, 2026, director Dr. Andrew Keller informed the company he will not seek or accept reelection to the Board of Directors after his current term ends. His term will expire at the company’s next annual shareholder meeting, at which point he will leave the board.
L1 Capital Global Opportunities Master Fund, Ltd. reports beneficial ownership of 111,535 Common Units of Sunshine Biopharma Inc., representing 4.99% of the class. This percentage is based on 2,123,635 Common Units outstanding as of May 28, 2026, as stated in a Definitive 14C Information Statement.
The filing notes exposure through 5,344,378 Series B Warrants and 400,000 Series C Warrants, each exercisable into common stock but subject to a 4.99% beneficial ownership limitation. L1 Capital holds sole voting and dispositive power over the 111,535 Common Units. Directors David Feldman and Joel Arber may be deemed beneficial owners under Rule 13d-3, but each disclaims beneficial ownership for all other purposes. The amendment also references an earlier filing covering 1,000,000 Common Units purchased on May 18, 2026.
Sunshine Biopharma Inc., a Colorado-based pharmaceutical company with generic and OTC operations in Canada and proprietary oncology/antiviral programs, reported second-quarter 2026 results. Q2 2026 revenue was $9,263,687, slightly below $9,410,230 a year earlier, as terminated distribution agreements reduced sales. Gross profit for the quarter was $2,426,682, and the company recorded a net loss of $1,564,048 ($1.15 per share).
For the first six months of 2026, revenue totaled $17,352,452 versus $18,311,571 in 2025, with a net loss of $2,807,917 ($2.95 per share). Operating expenses declined year over year, helped by the absence of a prior-period intangible impairment and lower consulting and R&D costs, partly offset by higher legal fees. Cash and cash equivalents were $13,748,301 at June 30, 2026, and total assets were $33,632,901.
Financing activities in the first half of 2026 provided $7,804,185 of cash, including a May 19, 2026 public offering of 1,200,000 units and warrant exercises. Subsequent to quarter-end, the company established a $4,000,000 at-the-market offering and raised $1,722,555 in net proceeds, received a U.S. patent for its coronavirus protease inhibitors, and continued development of its K1.1 mRNA liver cancer and SBFM-PL4 antiviral candidates.